S.T. Stent is developing a removable stent for use after Functional Endoscopic Sinus Surgery (FESS) to keep the sinus cavity open for almost a month, long enough for the tissue to heal.
The stent, for insertion after FESS, keeps the sinus cavity open up to 28 days, long enough for the sinus tissue to heal. The stent improves patient outcomes and reduces the probability of revision surgeries.
Founded: November 2013
Stage: Business development
Investors: The Trendlines Group, private investor
IP: One issued patent (United States), two pending (Canada, Europe, Japan, China)
Chronic sinusitis is constant inflammation of the sinus caused by infection or allergy and characterized by facial pain and pressure, nasal congestion, and headaches. When drug treatments fail, Functional Endoscopic Sinus Surgery (FESS) is performed to improve airflow within the nose and sinuses, improve drainage, and eliminate diseased tissue.
Unfortunately, up to 30% of sinus surgeries fail due to scarring and recurrent inflammation that closes the nasal openings and requires revision sinus surgery (RSNA RadioGraphics). According to Intersect ENT, the estimated sinus stent market opportunity exceeds $3 billion in the United States
There are more than 1 million FESS procedures performed annually in the United States and Europe.
Minimally invasive treatment of heart valve disease
A more efficient ablation catheter to treat atrial fibrillation
Preventing the development of pressure sores
Novel treatment for vertebral compression fractures
Preventing catheter-associated urinary tract infections (CAUTIs)
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer